FDA Approves Drug for AFib and Atrial Flutter in Critical Care Settings
The approval is based on clinical studies that demonstrated the IV treatment enables rapid management of the heart rate with minimal reduction of blood pressure.
The approval is based on clinical studies that demonstrated the IV treatment enables rapid management of the heart rate with minimal reduction of blood pressure.
Aprocitentan, targeting the endothelin pathway, offers a new approach for managing hypertension alongside existing medications.
The US Food and Drug Administration approved Medtronic’s Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest.
Read MoreMedStar Washington Hospital Center introduces the revolutionary RevCore procedure, the world’s first deep venous ‘stent cleaner.’ Vascular surgeon Dr. Steven Abramowitz successfully removes clots and debris from obstructed veins and stents in a single session, restoring blood flow and providing relief to patients suffering from venous stent failure.
Read MoreThe FDA’s approval of the world’s first dual-chamber leadless pacing system, Aveir DR, marks a significant milestone in cardiac treatment. This innovative technology opens up leadless pacemakers to a wider patient population, eliminating complications associated with pacemaker leads and revolutionizing cardiac pacing.
Read More